Dempsey reported that many of her patients with gut motility issues are doing fine on the low doses of the drug being used, and the mast cell paper reported that 9 of 14 of the patients in its case series with baseline nausea experienced reduced nausea after taking the drug
[14] [39] In December 2025, the FDA approved an oral version of semaglutide for weight management, using the same brand name (Wegovy) as the injectable version
This makes semaglutide one of the most effective weight loss medications available today.The amount of weight loss is clinically significant and can dramatically reduce the risk of obesity-related conditions such as type 2 diabetes, cardiovascular disease, sleep apnea, and joint problems
Though, they can also cease use right away
Most of this weight loss occurs in the first 32 weeks (9 months) and plateaus, as the body adapts to the medication and patients find a sustainable way of eating